Navigation Links
Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
Date:6/19/2013

s announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "goal", "should", "would", "project", "plan", "predict", "intend", "target" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, expected liquidity or achievements to differ materially from those projected in, or implied by, these forward-looking statements. Factors that may cause such a difference include, without limitation, our need for substantial additional financing and the availability and terms of any such financing, the safety and/or efficacy results of clinical trials of our product candidates, our failure to obtain regulatory approvals or comply with ongoing governmental regulation, our ability to commercialize, manufacture and achieve market acceptance of any of our product candidates, for which we rely heavily on collaboration with third parties, and our ability to protect and enforce our intellectual property rights and to operate without infringing upon the proprietary rights of third parties. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in managem
'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
2. Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma
3. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
4. Ibrutinib Expanded Access Program Open to Eligible U.S. Patients with Relapsed or Refractory Mantle Cell Lymphoma
5. Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
6. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
7. Ibrutinib Receives Two Oncology Breakthrough Therapy Designations from U.S. Food and Drug Administration
8. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
9. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
10. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
11. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... FRANCISCO , Nov. 25, 2014  goBalto, Inc., ... has been recognized as a winner of Red Herring,s ... a Global Top 100 North America award in 2013, ... international technology landscape. Red Herring,s Top 100 ... identifying promising new companies and entrepreneurs. Red Herring editors ...
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
(Date:11/26/2014)... BOULDER, Colo. , Nov. 25, 2014 ... ARRY ) today announced that its Chief ... speak at the following upcoming conferences.  The ... conferences through webcasts on the Array BioPharma ... ConferenceDate:Wednesday, December 3, 2014Time:1:30 p.m.  Eastern Time ...
Breaking Medicine Technology:goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Nanomix Receives ISO 13485:2003 Certification 2
... CONCORD, N.H., Oct. 5 A new statewide prescription assistance ... New Hampshire Rx Card will offer savings of up to ... across the country. All New Hampshire residents are eligible to ... can download a "FREE" card by visiting www.nhrxcard.com ...
... 5 BioWa, Inc. announced today that it ... Co. Ltd. (Otsuka) to provide Otsuka with access ... development and commercialization of their antibody therapeutics with ... Japanese pharmaceutical POTELLIGENT® License was initiated in May, ...
Cached Medicine Technology:New Hampshire Rx Card Launching Statewide 2BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical 2
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... 2014 Nearly 1,100 Risperdal lawsuits ... a consolidated litigation now underway in Pennsylvania state ... recently updated in the Philadelphia Court of Common ... proceeding, all of which involve a drug approved ... conditions. Many of the cases in this proceeding ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
(Date:11/27/2014)... Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals can ... a gluten-free diet, an expert says. Many traditional ... and cranberry sauce -- are gluten-free, but "when it ... need to be considered," Dr. Anca Safta, director of ... Forest Baptist Medical Center in North Carolina, said in ...
(Date:11/27/2014)... NY (PRWEB) November 27, 2014 The founders ... offering stylish, comfortable and high functioning compression socks, are proud ... newly-released socks use an innovative Gradient Pressure (TM) knitting technology ... blood. , VIM & VIGR’s commitment to adding flair and ... as just functional recently caught the eye of a writer ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
... a 50 meter radius of the venues of the ... said 27 medical response teams would be,deployed in all ... beginning,Sunday., ,Duque said the ban is part of ... the athletes as well as of the spectators., ...
... The age limit of Indians becoming sexually active is ... people in 15-19 years age, sexually transmitted infections, including ... that half the HIV infected people worldwide are between ... an official statement released today, the spokesperson of Christian ...
... An article published in the October issue of the journal Nutrition ... could end the search for a drug to beat prostate cancer.// ... cancer cells to commit "suicide." The researchers report that the drug ... growth plus it also caused "apoptosis". This is the natural process ...
... virus is conducted in Indonesia in order to eradicate ... 290 polio cases in the last six months.// ... of vaccination program this month end and they have ... provided vaccination to about 23.6 million children’s in Indonesia. ...
... innumerable benefits of fish oil for improvement of health ... might be good enough even in the prevention of ... ,Multiple Sclerosis is a disease characterized by ... disease is a significant problem for the patients. It ...
... Minister Dr Anbumani Ramadoss party was the first to raise ... Now he is trying to do a balancing act to diffuse ... need many more Khushboos to talk about safe sex to the ... marriage.’’, ,The minister said that his department had engaged ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: